Journal of the American Geriatrics Society · 2010
Homocysteine and mobility in older adults.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rolita Lydia, Holtzer Roee, Wang Cuiling, Lipton Richard B, Derby Carol A, Verghese Joe
Аннотация
OBJECTIVES: To determine the influence of homocysteine on mobility decline in older adults.
DESIGN: Prospective cohort.
SETTING: Einstein Aging Study, community-based aging study.
PARTICIPANTS: Five hundred seventy-four older adults without dementia (mean age 80.2 +/- 5.4, 61% women).
MEASUREMENTS: Mobility decline defined using gait velocity measurements at baseline and annual follow-up visits. Linear mixed effects models were used to adjust for age, sex, education, and other potential confounders.
RESULTS: Higher homocysteine levels were associated with slower gait velocity at baseline. Adjusted for age, sex, and education, a one-unit increase in baseline log homocysteine levels was associated with a 2.95-cm/s faster mobility decline per year (P=.01) over a median follow-up of 1.4 years. The 140 subjects in the highest quartile of homocysteine had a faster rate of mobility decline (1.75 cm/s per year faster, P=.01) than the 434 subjects in the lowest three quartiles of homocysteine (<or=15 micromol/L). The association between homocysteine and mobility decline remained robust even after adjusting for multiple confounders and accounting for the presence of clinical gait abnormalities.
CONCLUSION: Higher homocysteine levels are associated with greater risk of mobility decline in community-residing older adults.
DESIGN: Prospective cohort.
SETTING: Einstein Aging Study, community-based aging study.
PARTICIPANTS: Five hundred seventy-four older adults without dementia (mean age 80.2 +/- 5.4, 61% women).
MEASUREMENTS: Mobility decline defined using gait velocity measurements at baseline and annual follow-up visits. Linear mixed effects models were used to adjust for age, sex, education, and other potential confounders.
RESULTS: Higher homocysteine levels were associated with slower gait velocity at baseline. Adjusted for age, sex, and education, a one-unit increase in baseline log homocysteine levels was associated with a 2.95-cm/s faster mobility decline per year (P=.01) over a median follow-up of 1.4 years. The 140 subjects in the highest quartile of homocysteine had a faster rate of mobility decline (1.75 cm/s per year faster, P=.01) than the 434 subjects in the lowest three quartiles of homocysteine (<or=15 micromol/L). The association between homocysteine and mobility decline remained robust even after adjusting for multiple confounders and accounting for the presence of clinical gait abnormalities.
CONCLUSION: Higher homocysteine levels are associated with greater risk of mobility decline in community-residing older adults.